Novavax, Inc.
NVAX
$9.02
$0.54116.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -42.42% | 610.30% | -69.69% | -54.80% | -2.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.42% | 610.30% | -69.69% | -54.80% | -2.11% |
| Cost of Revenue | -42.43% | -31.43% | -57.06% | -28.16% | -45.92% |
| Gross Profit | -42.41% | 1,098.71% | -342.78% | -245.98% | 65.74% |
| SG&A Expenses | -53.23% | -42.17% | -52.75% | -37.70% | 18.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.29% | -35.23% | -54.98% | -31.44% | -28.48% |
| Operating Income | -34.81% | 471.95% | 31.64% | -3.33% | 131.05% |
| Income Before Tax | -34.71% | 457.80% | 58.36% | 6.95% | 184.43% |
| Income Tax Expenses | -57.10% | -46.95% | 341.29% | -48.06% | 1,641.96% |
| Earnings from Continuing Operations | -34.41% | 451.51% | 54.58% | 7.25% | 179.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.41% | 451.51% | 54.58% | 7.25% | 179.93% |
| EBIT | -34.81% | 471.95% | 31.64% | -3.33% | 131.05% |
| EBITDA | -34.63% | 514.23% | 34.62% | -2.46% | 115.93% |
| EPS Basic | -39.93% | 405.37% | 64.94% | 40.06% | 68.60% |
| Normalized Basic EPS | -40.72% | 424.82% | 47.61% | 41.94% | 37.52% |
| EPS Diluted | -38.09% | 378.28% | 64.94% | 40.06% | 70.87% |
| Normalized Diluted EPS | -39.41% | 394.50% | 47.61% | 41.94% | 43.28% |
| Average Basic Shares Outstanding | 9.19% | 15.10% | 29.56% | 54.74% | 66.04% |
| Average Diluted Shares Outstanding | 6.85% | 26.95% | 29.56% | 54.74% | 59.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |